Coverage
-
July 06, 2015
AstraZeneca LP and Cephalon Inc. have agreed to pay $46.5 million and $7.5 million, respectively, to resolve claims brought by a whistleblower in a False Claims Act suit accusing the drugmakers of knowingly underpaying for rebates owed to the Medicaid Drug Rebate Program, federal prosecutors announced on Monday.
2 other articles on this case.
View all »